Published in Women's Health Weekly, February 13th, 2003
EntreMed scientists found that Panzem, also referred to as 2-methoxyestradiol (or 2ME2), kills tumor cells and their supporting blood vessel cells by turning-on increased levels of a death receptor (Death Receptor 5 or DR5) that is located on the cell surface. In turn, this action triggers programmed cell death, or "apoptosis." DR5 may also serve as surrogate marker for assessing clinical responses to Panzem. Currently, Panzem is in phase I clinical trials for breast cancer and in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.